MAP2K7 and hepatocellular carcinoma: Sorafenib, approved by the FDA in 2007 as the first-line standard treatment for advanced hepatocellular carcinoma (HCC), targets critical tumor angiogenesis and proliferation pathways by inhibiting VEGFR1–3, PDGFRβ, and Raf-MEK-ERK signaling [1].